MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000547648

Медицинская библиотека · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025

Efficacy and Safety of Glibenclamide on Functional Outcomes and Cerebral Edema following Ischemic and Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Hegazi Amir, Mohamed Rashad G, Kashbour Muataz, Hussien Hussien O, Amin Ahmed Mostafa, Kassar Omar, Nashwan Abdulqadir J, Abouelmagd Moaz Elsayed

СтатьяСистематический обзорМетаанализПеревод пока не подготовлен

Аннотация

UNLABELLED: <p>

Objective

This systematic review and meta-analysis aimed to evaluate the clinical and radiological outcomes of glibenclamide versus control in acute stroke.

METHODS

In accordance with PRISMA guidelines, a comprehensive literature search was conducted to identify relevant studies up to January 15, 2025. Efficacy outcomes included modified Rankin Scale (mRS) score at 3 and 6 months, Barthel index, midline shift at 72-96 h, serum matrix metalloproteinase-9 levels, and decompressive craniectomy. Safety analysis assessed the incidence of hypoglycemia, mortality, and serious adverse events (SAEs).

RESULTS

A total of seven randomized controlled trials involving 1,225 patients were included in the meta-analysis. No statistically significant differences were observed in the efficacy outcomes in the pooled analysis. In subgroup analysis of mRS, glibenclamide was superior in intracerebral hemorrhage (mean difference [MD] = -0.67, 95% confidence interval [CI] [-1, -0.34], p value <0.0001) but not ischemic or subarachnoid hemorrhage subtypes (MD = -0.03, 95% CI [-0.34, 0.28], p value = 0.86) and (MD = 0.06, 95% CI [-0.6, 0.71], p value = 0.86), respectively. In terms of safety, there were no significant differences in SAE or mortality (odds ratio [OR] = 1.34, 95% CI [0.99, 1.8], p value = 0.06) and (OR = 0.67, 95% CI [0.31, 1.45], p value = 0.31), respectively. However, glibenclamide was associated with an increased risk of hypoglycemia (OR = 5.03, 95% CI [2.17, 11.66], p value = 0.0002).

CONCLUSION

The use of glibenclamide did not demonstrate improved outcomes in patients with acute stroke. However, real-time pharmacokinetic monitoring, identifying optimal administration route, and patient subgroups, which may potentially benefit from glibenclamide are essential before the drug's efficacy can be conclusively determined. </p>.

Для цитирования: Hegazi Amir, Mohamed Rashad G, Kashbour Muataz, Hussien Hussien O, Amin Ahmed Mostafa, Kassar Omar, Nashwan Abdulqadir J, Abouelmagd Moaz Elsayed. Efficacy and Safety of Glibenclamide on Functional Outcomes and Cerebral Edema following Ischemic and Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2025. DOI: 10.1159/000547648.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.